Palvella Therapeutics, Inc. Paid-in-Kind Interest
Palvella Therapeutics, Inc. (PVLA) reported Paid-in-Kind Interest of $2.59 million for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-23.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2016-03-23
- Palvella Therapeutics, Inc. paid-in-kind interest for the quarter ending 2014-12-31 was $2.22M.
- Palvella Therapeutics, Inc. paid-in-kind interest for the quarter ending 2014-09-30 was $183.30K.
- Palvella Therapeutics, Inc. paid-in-kind interest for the quarter ending 2014-06-30 was $99.72K.
- Palvella Therapeutics, Inc. paid-in-kind interest for the quarter ending 2014-03-31 was $82.23K.
- Palvella Therapeutics, Inc. paid-in-kind interest for fiscal 2014 was $2.59M, a 524.96% increase from fiscal 2013.
- Palvella Therapeutics, Inc. paid-in-kind interest for fiscal 2013 was $414.27K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2014-12-31 | $2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $2.41M derived: sum of 2 quarters · filed 2016-03-23 | $2.51M derived: sum of 3 quarters · filed 2016-03-23 | $2.59M 10-K · filed 2016-03-23 |
| 2014-09-30 | $183.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $283.02K derived: sum of 2 quarters · filed 2015-11-13 | $365.25K 10-Q · filed 2015-11-13 | |
| 2014-06-30 | $99.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $181.95K 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | $82.23K 10-Q · filed 2015-05-14 | |||
| 2013-12-31 | $414.27K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |